Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation

Atrial Fibrillation Friday, June 21st, 2013

Circulation: April 3, 2013,

Background—Pulmonary vein isolation (PVI) for atrial fibrillation is associated with a transient increased risk of thromboembolic and hemorrhagic events. We hypothesized that dabigatran can be safely used as an alternative to continuous warfarin for the periprocedural anticoagulation in PVI.

Methods and Results—A total of 999 consecutive patients undergoing PVI were included; 376 patients were on dabigatran (150 mg), and 623 patients were on warfarin with therapeutic international normalization ration. Dabigatran was held 1 to 2 doses before PVI and restarted at the conclusion of the procedure or as soon as patients were transferred to the nursing floor.   Read more

National Minority Quality Forum Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.